Clinical Scorecard: Does Initial Atopic Dermatitis Severity Affect Long-Term Abrocitinib Outcomes? A Post Hoc Analysis of Two Randomized Trials

At a Glance

Key Highlights

• The post hoc pooled analysis evaluated short-term efficacy and safety at week 16 and long-term efficacy and safety through week 112 by baseline disease-severity subgroup.
• Baseline severity was classified as moderate or severe using specified PtGA, EASI/IGA, or body-surface-area criteria; PtGA was excluded from the long-term classification.
• The article summary reports rapid, durable improvements in skin clearance and itch across baseline severity subgroups, irrespective of the severity-assessment method.
• The analysis included two phase 3 studies, JADE COMPARE and JADE EXTEND; the long-term assessment was a planned interim evaluation of the ongoing JADE EXTEND trial.

Guideline-Based Recommendations

Diagnosis

• The analysis classified baseline severity post hoc: PtGA score 3 for moderate and 4 for severe; EASI 16–25 with IGA 3 for moderate or EASI >25 with IGA 4 for severe; or BSA involvement of 10–30% for moderate or >30% for severe.

Management

• The article states that current guidelines recommend systemic immunosuppressive therapy, specified biologics, and oral JAK inhibitors for moderate-to-severe atopic dermatitis; baricitinib is listed outside the USA.
• Abrocitinib is described as an approved oral once-daily JAK1-selective inhibitor for adults and adolescents aged 12 years or older with moderate-to-severe atopic dermatitis.

Monitoring & Follow-up

• Trial efficacy assessments included IGA response, EASI-75, EASI-90 combined with PP-NRS 0/1, and PP-NRS4.
• IGA response required a score of 0 or 1 and a reduction of at least 2 points from baseline; PP-NRS4 required a reduction of at least 4 points.

Risks

• The provided article text does not report specific adverse-event findings or risk estimates.

Patient & Prescribing Data

Participants had at least 1 year of atopic dermatitis and moderate-to-severe baseline disease, with inadequate response to topical medicated therapy for at least 4 weeks or a need for systemic therapy. JADE COMPARE enrolled adults; JADE EXTEND included patients aged 12 years or older.

JADE COMPARE included abrocitinib 100 mg or 200 mg orally once daily for 16 weeks with topical medicated therapy, as well as comparator arms. JADE EXTEND assessed abrocitinib 100 mg or 200 mg once daily, with or without topical corticosteroids, through week 112.

Clinical Best Practices

• The source notes that severity instruments are not standardized across clinics; interpret the reported subgroups according to the specific post hoc classification criteria used.
• The short-term JADE COMPARE regimens combined study treatment with topical medicated therapy.
• The long-term findings described are from a planned interim evaluation of an ongoing extension trial.

Related Resources & Content

• JADE COMPARE, ClinicalTrials.gov
• JADE EXTEND, ClinicalTrials.gov